Haisco Pharmaceutical Group Co., Ltd.

SZSE:002653 Stock Report

Market Cap: CN¥35.2b

Haisco Pharmaceutical Group Balance Sheet Health

Financial Health criteria checks 5/6

Haisco Pharmaceutical Group has a total shareholder equity of CN¥4.2B and total debt of CN¥2.1B, which brings its debt-to-equity ratio to 49.4%. Its total assets and total liabilities are CN¥6.9B and CN¥2.7B respectively. Haisco Pharmaceutical Group's EBIT is CN¥380.0M making its interest coverage ratio -3.5. It has cash and short-term investments of CN¥1.3B.

Key information

49.4%

Debt to equity ratio

CN¥2.07b

Debt

Interest coverage ratio-3.5x
CashCN¥1.29b
EquityCN¥4.18b
Total liabilitiesCN¥2.73b
Total assetsCN¥6.91b

Recent financial health updates

Recent updates

Is Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) Trading At A 38% Discount?

Dec 19
Is Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) Trading At A 38% Discount?

Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) Shares May Have Run Too Fast Too Soon

Nov 19
Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) Shares May Have Run Too Fast Too Soon

Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations

Aug 22
Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations

With Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) It Looks Like You'll Get What You Pay For

Jul 25
With Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) It Looks Like You'll Get What You Pay For

Haisco Pharmaceutical Group (SZSE:002653) Has A Pretty Healthy Balance Sheet

Jul 04
Haisco Pharmaceutical Group (SZSE:002653) Has A Pretty Healthy Balance Sheet

Calculating The Fair Value Of Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

Jun 17
Calculating The Fair Value Of Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

These 4 Measures Indicate That Haisco Pharmaceutical Group (SZSE:002653) Is Using Debt Reasonably Well

Mar 19
These 4 Measures Indicate That Haisco Pharmaceutical Group (SZSE:002653) Is Using Debt Reasonably Well

Risks To Shareholder Returns Are Elevated At These Prices For Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

Feb 27
Risks To Shareholder Returns Are Elevated At These Prices For Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

Financial Position Analysis

Short Term Liabilities: 002653's short term assets (CN¥2.9B) exceed its short term liabilities (CN¥1.4B).

Long Term Liabilities: 002653's short term assets (CN¥2.9B) exceed its long term liabilities (CN¥1.3B).


Debt to Equity History and Analysis

Debt Level: 002653's net debt to equity ratio (18.6%) is considered satisfactory.

Reducing Debt: 002653's debt to equity ratio has increased from 47.3% to 49.4% over the past 5 years.

Debt Coverage: 002653's debt is well covered by operating cash flow (24.8%).

Interest Coverage: 002653 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 14:47
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Haisco Pharmaceutical Group Co., Ltd. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yue GaoChangjiang Securities Co. LTD.
Shanshan LiChina Merchants Securities Co. Ltd.
Sophia ZhangChina Stock Investment Research Co. Ltd. (GZ500..com)